de Vries, F. ., Bracke, M. ., Leufkens, H. G., Lammers, J. W., Cooper, C. ., & van Staa, T. P. (2007). Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. http://doi.org/10.1002/art.22294
H. Leufkens
First name
H.
Middle name
G.
Last name
Leufkens
van de Garde, E. M., Souverein, P. C., Hak, E. ., Deneer, V. H., van den Bosch, J. M., & Leufkens, H. G. (2007). Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens. http://doi.org/10.1097/HJH.0b013e328010520a
van Staa, T. P., Smeeth, L. ., Persson, I. ., Parkinson, J. ., & Leufkens, H. G. (2008). Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.1568
van Staa, T. P., Smeeth, L. ., Persson, I. ., Parkinson, J. ., & Leufkens, H. G. (2008). What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol. http://doi.org/10.1093/ije/dym296
Willemen, M. J., Mantel-Teeuwisse, A. K., Straus, S. M., Leufkens, H. G., & Egberts, A. C. (2008). Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs. Obesity (Silver Spring). http://doi.org/10.1038/oby.2008.362
van Staa, T. P., Cooper, C. ., Barlow, D. ., & Leufkens, H. G. (2008). Individualizing the risks and benefits of postmenopausal hormone therapy. Menopause. http://doi.org/10.1097/gme.0b013e31812e558f
van Staa, T. P., Rietbrock, S. ., Setakis, E. ., & Leufkens, H. G. (2008). Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. J Intern Med. http://doi.org/10.1111/j.1365-2796.2008.01991.x
Setakis, E. ., Leufkens, H. G., & van Staa, T. P. (2008). Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum. http://doi.org/10.1002/art.23925
van Staa, T. P., Leufkens, H. G., Zhang, B. ., & Smeeth, L. . (2009). A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med. http://doi.org/10.1371/journal.pmed.1000194
Bazelier, M. T., Van Staa, T. ., Uitdehaag, B. M., Cooper, C. ., Leufkens, H. G., Vestergaard, P. ., … de Vries, F. . (2011). The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res. http://doi.org/10.1002/jbmr.418